Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Published on November 28, 2012 at 5:05 AM · No Comments

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete. Recruitment is ongoing at sites located around the world, including in the U.S., where sites are ready to enroll eligible patients.

The TRUST trial is designed to evaluate the safety and efficacy of the investigational compound BAY 86-6150, a recombinant factor VIIa (rFVIIa) protein in patients with hemophilia A or hemophilia B who have developed neutralizing antibodies, called inhibitors.

"Bayer is committed to finding innovative ways to meet the needs of people with hemophilia, including those affected by the effects of inhibitors to clotting factor replacement therapies," said Pamela Cyrus, MD, Vice President and Head, U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.

Source:

Bayer HealthCare Pharmaceuticals Inc.
 

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Telemedicine in action: an interview with Ian Jackson, Managing Director, Imerja